DaVita Inc. (NYSE:DVA) Shares Acquired by Victory Capital Management Inc.

Victory Capital Management Inc. increased its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 138.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 83,062 shares of the company's stock after buying an additional 48,196 shares during the period. Victory Capital Management Inc. owned about 0.09% of DaVita worth $8,702,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. Sivik Global Healthcare LLC acquired a new stake in shares of DaVita during the fourth quarter worth $4,714,000. Gitterman Wealth Management LLC boosted its stake in DaVita by 20.6% in the fourth quarter. Gitterman Wealth Management LLC now owns 2,698 shares of the company's stock worth $283,000 after purchasing an additional 460 shares in the last quarter. Truist Financial Corp grew its stake in shares of DaVita by 54.4% during the fourth quarter. Truist Financial Corp now owns 26,068 shares of the company's stock valued at $2,731,000 after purchasing an additional 9,180 shares during the last quarter. Bryn Mawr Capital Management LLC raised its position in shares of DaVita by 20.7% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 3,500 shares of the company's stock worth $367,000 after acquiring an additional 600 shares during the last quarter. Finally, Atria Wealth Solutions Inc. boosted its holdings in DaVita by 37.8% during the fourth quarter. Atria Wealth Solutions Inc. now owns 4,745 shares of the company's stock worth $497,000 after buying an additional 1,301 shares during the last quarter. Institutional investors own 90.12% of the company's stock.

Wall Street Analysts Forecast Growth

DVA has been the topic of several research reports. StockNews.com downgraded shares of DaVita from a "strong-buy" rating to a "buy" rating in a research note on Monday, May 6th. Barclays lifted their price target on shares of DaVita from $133.00 to $150.00 and gave the company an "equal weight" rating in a research report on Monday, May 6th. UBS Group increased their target price on shares of DaVita from $113.00 to $134.00 and gave the company a "buy" rating in a research report on Wednesday, February 14th. Truist Financial boosted their price target on shares of DaVita from $130.00 to $135.00 and gave the company a "hold" rating in a research report on Tuesday, February 20th. Finally, TheStreet raised DaVita from a "c+" rating to a "b-" rating in a research note on Wednesday, February 7th. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $129.75.

DaVita Price Performance

DVA stock traded up $0.42 during trading on Tuesday, hitting $137.01. The stock had a trading volume of 581,526 shares, compared to its average volume of 837,650. The stock has a market capitalization of $12.02 billion, a P/E ratio of 15.57, a PEG ratio of 1.07 and a beta of 1.04. The company has a debt-to-equity ratio of 7.95, a current ratio of 1.43 and a quick ratio of 1.37. The company's 50-day moving average price is $134.97 and its two-hundred day moving average price is $115.53. DaVita Inc. has a twelve month low of $71.51 and a twelve month high of $145.04.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $2.38 earnings per share for the quarter, beating analysts' consensus estimates of $1.95 by $0.43. DaVita had a net margin of 6.61% and a return on equity of 68.52%. The business had revenue of $3.07 billion for the quarter, compared to analyst estimates of $3.03 billion. During the same period last year, the business earned $1.58 EPS. The company's revenue was up 6.9% on a year-over-year basis. As a group, research analysts predict that DaVita Inc. will post 9.49 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Javier Rodriguez sold 67,603 shares of the business's stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $126.11, for a total value of $8,525,414.33. Following the completion of the sale, the chief executive officer now directly owns 488,697 shares in the company, valued at $61,629,578.67. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Barbara J. Desoer sold 5,030 shares of the business's stock in a transaction on Friday, May 10th. The stock was sold at an average price of $138.81, for a total transaction of $698,214.30. Following the sale, the director now directly owns 10,954 shares of the company's stock, valued at $1,520,524.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Javier Rodriguez sold 67,603 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the sale, the chief executive officer now owns 488,697 shares of the company's stock, valued at $61,629,578.67. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 139,570 shares of company stock valued at $17,249,285. Corporate insiders own 1.40% of the company's stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.